Kodiak Sciences Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing
Stocks · News reference
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126
HC Wainwright & Co. analyst Matthew Caufield maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and raises the price target from $96 to $126.
Top 3 Health Care Stocks That May Collapse In Q4
Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.
MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing and Nvidia: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51,481.51.
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850
Evercore ISI has updated its price target for Regeneron Pharmaceuticals, raising it from $850 to $900.
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.